Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Open-Label, Active-Controlled Study of ALXN1210 Versus Eculizumab in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab

X
Trial Profile

A Phase 3, Randomized, Open-Label, Active-Controlled Study of ALXN1210 Versus Eculizumab in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 Nov 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ravulizumab (Primary) ; Eculizumab
  • Indications Paroxysmal nocturnal haemoglobinuria
  • Focus Registrational; Therapeutic Use
  • Acronyms Study 302
  • Sponsors Alexion AstraZeneca Rare Disease
  • Most Recent Events

    • 15 Jun 2023 Results assessing clinical trial and real-world prevalence of csEVH in patients with PNH who were clinically stable on C5itreatment, and real-world physician-reported disease control and patient QoL, and physician- and patient-reported treatment satisfaction presented at the 28th Congress of the European Haematology Association.
    • 15 Jun 2023 Results of clinical efficacy and safety of ravulizumab maintenance treatment for up to 4 years in complement inhibitor-experienced patients with PNH, presented at the 28th Congress of the European Haematology Association
    • 01 Sep 2022 Results assessing long-term outcomes from two clinical studies (Study 301 and Study 302) from 27 weeks to two years published in the European Journal of Haematology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top